In a strategic leap that underscores the growing importance of next-generation biologics, Regeneron Pharmaceuticals (NASDAQ: REGN) announced a license and collaboration agreement with ModeX Therapeutics, an OPKO-owned biotech, potentially worth over $1 billion. The deal brings together ModeX’s MSTAR multispecific platform and Regeneron’s proven antibody discovery capabilities with the goal of developing multispecific antibodies that address multiple disease pathways in a single molecule.
Multispecific antibodies are increasingly recognized as powerful tools instead of binding a single target, they can engage multiple receptors or ligands in a coordinated way. This collaboration represents a way to “increase our shots on goal by identifying more candidates faster,” according to its Chief Scientific Officer. By pairing its proprietary binders with ModeX’s modular MSTAR platform, Regeneron can potentially unlock new therapeutic avenues in oncology, immunology, and metabolic diseases.
Under the agreement, ModeX receives a $7 million upfront payment, followed by milestone payments exceeding $200 million per selected molecule if development advances. On top of that, ModeX is eligible for tiered global net-sales royalties in the low double digits. Regeneron, for its part, will carry forward all preclinical, clinical, and commercialization costs for the assets it elects to develop. If multiple antibody programs advance, the total deal value could surpass $1 billion, a figure that underscores Regeneron’s commitment to next-gen biologic modalities.